Analysis Ipsen S.A. (0MH6)
6/3/2024
Analysis of Ipsen S.A. (0MH6)
I'm sorry, but the data you provided seems to be related to a financial instrument (0MH6) rather than Ipsen S.A., which is a pharmaceutical company. If you could provide me with the relevant financial data for Ipsen S.A., I would be happy to help you with a short analysis.Earnings
The company's results for the most recent quarter, ending on April 30, 2025, have not been provided at this time. The previous quarter's results, ending on February 27, 2025, were handled by the Transfer Agent. The quarter before that, ending on January 31, 2025, had results released after hours. The results for the quarter ending on October 31, 2024, were not provided at the time. However, for the quarter ending on August 1, 2024, the company had an EPS estimate of 1.32.Main Statystic ðŸ§
The company's financials show a strong cash flow, with operating cash flow at $110.56 billion and levered free cash flow at $84.73 billion. The balance sheet indicates a total cash of $67.15 billion and total debt of $104.59 billion, resulting in a current ratio of 1.037. The company's book value per share is $4.837, total cash per share is $4.379, and total debt to equity ratio is 140.968.In terms of profitability, the company has a profit margin of 26.31% and an operating margin of 30.74%. The fiscal year ends on September 30, 2023. The income statement shows EBITDA of $131.39 billion, revenue of $381.62 billion, and net income to common of $100.39 billion. The company has a diluted EPS of $6.43, gross profit of $169.15 billion, revenue per share of $24.54, and has experienced negative quarterly revenue and earnings growth.
The company has a return on assets of 22.07% and a return on equity of 147.25%. In terms of stock statistics, the short ratio is 1.53, with 99.29 million shares shorted out of 15.31 billion float shares. The stock has a market capitalization of $2.92 trillion.
Valuation metrics include a PEG ratio of 26.32, forward PE of 26.32, trailing PE of 29.59, price to book ratio of 39.34, price to sales ratio of 7.65, enterprise value of $2.95 trillion, enterprise to EBITDA of 22.76, and enterprise to revenue of 7.73.
The stock price summary shows a beta of 1.26, with a 50-day moving average of $176.26 and a 200-day moving average of $181.04. The stock's 52-week low is $164.08, high is $199.62, and has seen a 52-week change of 6.85%.
In terms of dividends and splits, the company has a payout ratio of 14.93% and a forward annual dividend rate of 1. The stock's dividend dates are on May 16 and the ex-dividend date is on May 10. The company has a 5-year average dividend yield of 0.73% and a trailing annual dividend yield of 0.51%. The last stock split was a 4-for-1 split on August 31, 2020.
Income statement 💸
These are the revenue figures. Here are the conclusions:1. The company's sales revenue has been increasing steadily over the years, from $274.5 billion in 2020 to $383.3 billion in 2023.
2. Despite the increase in sales, the cost of goods sold has also been rising, indicating a potential challenge in managing production or procurement costs.
3. The gross profit margin has fluctuated slightly but remained relatively stable over the years.
4. Operating income has shown an increasing trend, reaching $114.3 billion in 2023.
5. Net income has also been on the rise, reaching $97 billion in 2023.
6. Earnings per share (EPS) have shown a slight fluctuation but have generally increased over the years.
7. The company has been able to maintain a consistent number of outstanding shares, which is important for investors to assess the dilution of their ownership.
8. Overall, the financial performance of the company seems to be positive, with increasing revenues and profits over the years.
Earnings estimate
Based on the analysts' estimates for future quarterly and annual earnings per share (EPS):1. For the current quarter ending on June 30, 2024, the average EPS estimate is $1.23, with a low estimate of $1.18 and a high estimate of $1.26. This shows an improvement compared to the EPS of $1.17 from the same quarter a year ago.
2. For the next quarter ending on September 30, 2024, the average EPS estimate is $1.42, with a low estimate of $1.33 and a high estimate of $1.51. This also indicates growth from the EPS of $1.35 in the same quarter last year.
3. Looking at the estimates for the current year ending on September 30, 2024, the average EPS estimate is $6.10, ranging from a low estimate of $5.95 to a high estimate of $6.41. This reflects an increase from the EPS of $5.67 for the previous year.
4. For the next year ending on September 30, 2025, the average EPS estimate is $6.69, with a low estimate of $5.92 and a high estimate of $7.31. This suggests a growth trajectory from the EPS of $6.10 in the current year.
Overall, the analysts' estimates point towards a positive outlook for the company's earnings per share, showing a trend of expected growth in both the short term and the long term.
Revenue estimate
Based on the analysts' estimates for the future quarterly and annual sales of the company, we can draw the following conclusions:1. For the current quarter ending on June 30, 2024, the average sales estimate is $77,545,400,000, with a sales growth of 2% compared to the same quarter last year. The number of analysts providing estimates is 25.
2. For the next quarter ending on September 30, 2024, the average sales estimate is $85,501,800,000, with a sales growth of 3% compared to the same quarter last year. The number of analysts providing estimates is 25.
3. For the current fiscal year ending on September 30, 2024, the average sales estimate is $357,772,000,000, with a sales growth of 1% compared to the previous fiscal year. The number of analysts providing estimates is 38.
4. For the next fiscal year ending on September 30, 2025, the average sales estimate is $380,772,000,000, with a sales growth of 6% compared to the current fiscal year. The number of analysts providing estimates is 38.
Overall, the analysts are generally optimistic about the company's future sales performance, with moderate growth expected in both the quarterly and annual sales figures.
Growth estimates
Based on the consensus estimates provided by analysts, we can draw the following conclusions regarding the growth rate of the company for different periods:1. Current Quarter: The estimated growth rate for the current quarter is 5.1%.
2. Next Quarter: The estimated growth rate for the next quarter is 5.2%.
3. Current Year: The estimated growth rate for the current year is 7.6%.
4. Next Year: The estimated growth rate for the next year is 9.7%.
5. Past 5 Years (per annum): The average annual growth rate for the past 5 years is 20.1%.
6. Next 5 Years (per annum): The estimated average annual growth rate for the next 5 years is 9.7%.
These estimates suggest a positive growth trend for the company, with a slightly lower growth rate expected in the next 5 years compared to the past 5 years. It indicates a steady but slightly slower growth trajectory for the company in the near future.
Price target
The analysts' forecast for the future price of the security is as follows:- Low: $164
- High: $275
- Median: $201.43
- Average: $204.58
- Current price: $192.25
- Currency: USD
Based on these forecasts, we can see that the analysts have a range of opinions on the future price of the security, with the low end at $164, the high end at $275, and the average at $204.58. The current price of the security is $192.25, which falls below the median and average forecasted prices. Investors should consider these forecasts along with other factors when making decisions about buying or selling the security.
Balance Sheet
These are balance sheets. Here are the conclusions:1. The total assets have been increasing over the years, reaching $365,725,000,000 in 2018.
2. Current assets include cash, inventory, and receivables, with a significant portion in cash equivalents and short-term investments.
3. Non-current assets consist mainly of investments and advances, along with machinery, furniture, and equipment.
4. Total liabilities have also been increasing, but at a slower pace compared to assets.
5. Shareholders' equity has shown a positive trend, indicating a healthy financial position.
6. The company has been investing in leases, land, and improvements, reflecting a focus on long-term growth.
7. Accumulated depreciation is significant, suggesting the company has been using its assets efficiently.
8. The company has been managing its debt levels, with a mix of short-term and long-term debt.
9. Overall, the financial health of the company seems stable and improving over the years.
Cash Flow 💶
This is the cash flow statement. Here are some conclusions we can draw from the data:1. The company's free cash flow has been fluctuating over the years, with the highest value in 2022 and the lowest in 2020.
2. Operating cash flow has generally been increasing year over year, indicating improved operational efficiency.
3. The company has been consistently paying interest and income taxes, with varying amounts each year.
4. The end cash position has also been fluctuating, reaching its highest value in 2020.
5. Financing activities show significant variability, with large amounts being spent on common stock repurchase and debt issuance and payments.
6. Investing activities also vary, with significant amounts being spent on the sale and purchase of investments, as well as capital expenditures.
7. Overall, the company seems to be managing its cash flow effectively, but there are fluctuations in different areas that may require further analysis.
MACD of 0MH6
This is not investment advice. Remember to verify the information provided here.
Get access to the full analysis
- Over 35 000 indexes
- CFD, Forex, Crypto and Stocks Exchange
- Over 150 Indicators
- Pattern and candle analysis
- Support and resistance levels
- Fundamental, technical and sentimental analysis
- Power from AI
